RemeGen Co., Ltd.

Equities

9995

CNE1000048G6

Biotechnology & Medical Research

Delayed Hong Kong S.E. 10:58:24 2024-03-18 pm EDT 5-day change 1st Jan Change
28.35 HKD -4.71% Intraday chart for RemeGen Co., Ltd. +17.92% -24.43%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
RemeGen Co., Ltd.(XSSC:688331) added to FTSE All-World Index CI
RemeGen Co. Ltd. Presents Oral Presentation on Evaluation of its Proprietary Disitamab Vedotin for Cervical Cancer At ESGO 2024 CI
RemeGen's 2023 Net Loss Widens; Revenue Jumps 40% MT
RemeGen Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
RemeGen's Loss to Widen in 2023 MT
RemeGen Co., Ltd. Provides Earnings Guidance for the Period from January 1, 2023 to December 31, 2023 CI
RemeGen Buys Back HK$12 Million Worth of Hong Kong Shares MT
RemeGen Denies Rumors of Tight Cash Flow, Funding Hurdles MT
RemeGen's Rc88 Obtains FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients CI
RemeGen Co., Ltd.'s Pioneering RC88 Receives IND Approval from US FDA for Platinum-Resistant Recurrent Ovarian Cancer Treatment CI
RemeGen Gets Full Approval for Telitacicept MT
RemeGen Co., Ltd. Announces the Full Approval of. Telitacicept for. Systemic Lupus erythematosus by NMPA CI
RemeGen to Hike Annual Caps for Services Agreements MT
RemeGen Co., Ltd. to Present telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in A Late-Breaking Abstract Oral Presentation Session At the American College of Rheumatology CI
RemeGen Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Biotech Firm RemeGen Appoints CFO MT
RemeGen Names CFO MT
Remegen Co., Ltd. Appoints Tong Shaojing as the Chief Financial Officer CI
Remegen Co., Ltd. Appoints Tong Shaojing as Joint Company Secretary CI
RemeGen CFO Steps Down; Shares Tumble 5% in Shanghai MT
RemeGen Co., Ltd. Announces Resignation of Li Jia as Joint Company Secretary CI
Remegen Co., Ltd. Announces Resignation of Li Jia as Chief Financial Officer CI
ImmuneOnco Biopharmaceuticals Raises HK$234.5 Million in Hong Kong IPO MT
ImmuneOnco Biopharmaceuticals Launches Up to HK$319 Million Hong Kong IPO MT
RemeGen Completes Phase III Study of Arthritis Drug in China MT
Chart RemeGen Co., Ltd.
More charts
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The Company is mainly engaged in the discovery, development and commercialization of therapeutic antibody drugs such as antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company's main products include tetacept (RC18), veldicitumab (RC48) and dual-target fusion protein (RC28). The Company's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The Company mainly conducts its businesses in the domestic market.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
27.38 CNY
Average target price
42.71 CNY
Spread / Average Target
+55.97%
Consensus
  1. Stock
  2. Equities
  3. Stock RemeGen Co., Ltd. - Hong Kong S.E.
  4. News RemeGen Co., Ltd.
  5. RemeGen Shareholders to Vote Dec. 20 on Employee Incentive Tied to Shanghai IPO